US · Healthcare · Biotechnology
EPS came in at -1.05 against a street estimate of -0.98 — a miss of 7.1%.
Analysts rate ArriVent BioPharma, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $44.70.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 8.93% |
| Hillhouse Capital Advisors, Ltd. | 7.97% |
| Orbimed Advisors LLC | 6.14% |
| FMR Inc | 6.12% |
| BlackRock Inc | 5.13% |
| Octagon Capital Advisors LP | 4.00% |
| Novo A/S | 3.94% |
| Sofinnova Ventures | 3.44% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ARRIVENT BIOPHARMA, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $154.7 million in cash and cash equivalents as of June 30, 2026, u | 2026-08-12 |
| Results announced · Q3 2026 ARRIVENT BIOPHARMA Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $373.1 million as of June 30, 2026 • Expected to fund operatio | 2026-08-12 |
| Shareholder vote results · Q2 2026 ARRIVENT BIOPHARMA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company held 2026 annual stockholder meeting on June 18, 2026 • 46,368,442 shares of commo | 2026-06-22 |
| Quarterly report · Q1 2026 ARRIVENT BIOPHARMA, INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and investments: $326.4 million (cash $62.1M + short-term investments $264.3M) as | 2026-05-11 |
| Company announcement · Q2 2026 ARRIVENT BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company authorized to offer up to $250,000,000 in common stock through an "at the mar | 2026-05-11 |
| Results announced · Q2 2026 ARRIVENT BIOPHARMA Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $326.4 million as of March 31, 2026 • Cash runway: expected to | 2026-05-11 |
| Proxy statement · Q2 2026 ARRIVENT BIOPHARMA, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Directors – Vote to elect three directo | 2026-04-28 |
| Annual report FY2025 ARRIVENT BIOPHARMA, INC. — 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $762,664,165 • Shares outstanding | 2026-03-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive license agreement for ARR-002 in Greater China region ArriVent BioPharma signed a licensing deal with Shanghai Allist Pharmaceuticals on August 11, 2026, granting Allist exclusive rights to develop and commercialize ARR-002 (an antibody-drug co | 2026-08-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ArriVent BioPharma, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.